China Plasma Protease C1-inhibitor Market Size & Outlook

The plasma protease c1-inhibitor market in China is expected to reach a projected revenue of US$ 371.5 million by 2030. A compound annual growth rate of 9% is expected of China plasma protease c1-inhibitor market from 2024 to 2030.
Revenue, 2023 (US$M)
$203.0
Forecast, 2030 (US$M)
$371.5
CAGR, 2024 - 2030
9%
Report Coverage
China

China plasma protease c1-inhibitor market, 2018-2030 (US$M)

China

China plasma protease c1-inhibitor market highlights

  • The China plasma protease c1-inhibitor market generated a revenue of USD 203.0 million in 2023 and is expected to reach USD 371.5 million by 2030.
  • The China market is expected to grow at a CAGR of 9% from 2024 to 2030.
  • In terms of segment, c1-inhibitors was the largest revenue generating drug class in 2023.
  • Selective Bradykinin B2 Receptor Antagonist is the most lucrative drug class segment registering the fastest growth during the forecast period.


Plasma protease c1-inhibitor market data book summary

Market revenue in 2023USD 203.0 million
Market revenue in 2030USD 371.5 million
Growth rate9% (CAGR from 2023 to 2030)
Largest segmentC1-inhibitors
Fastest growing segmentSelective Bradykinin B2 Receptor Antagonist
Historical data2018 - 2022
Base year2023
Forecast period2024 - 2030
Quantitative unitsRevenue in USD million
Market segmentationC1-inhibitors, Kallikrein Inhibitor, Selective Bradykinin B2 Receptor Antagonist
Key market players worldwideCSL Ltd, Takeda Pharmaceutical Co Ltd, Pharming Group, KalVista Pharmaceuticals Inc, Sanquin, BioCryst Pharmaceuticals Inc, Centogene NV Ordinary Shares


Other key industry trends

  • In terms of revenue, China accounted for 6.1% of the global plasma protease c1-inhibitor market in 2023.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
  • In Asia Pacific, India plasma protease c1-inhibitor market is projected to lead the regional market in terms of revenue in 2030.
  • India is the fastest growing regional market in Asia Pacific and is projected to reach USD 378.0 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Plasma Protease C1-inhibitor Market Companies

Name Profile # Employees HQ Website

China plasma protease c1-inhibitor market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to plasma protease c1-inhibitor market will help companies and investors design strategic landscapes.


C1-inhibitors was the largest segment with a revenue share of 53.15% in 2023. Horizon Databook has segmented the China plasma protease c1-inhibitor market based on c1-inhibitors, kallikrein inhibitor, selective bradykinin b2 receptor antagonist covering the revenue growth of each sub-segment from 2018 to 2030.


Reasons to subscribe to China plasma protease c1-inhibitor market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of China plasma protease c1-inhibitor market databook

  • Our clientele includes a mix of plasma protease c1-inhibitor market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the China plasma protease c1-inhibitor market , including forecasts for subscribers. This country databook contains high-level insights into China plasma protease c1-inhibitor market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

China plasma protease c1-inhibitor market size, by drug class, 2018-2030 (US$M)

China Plasma Protease C1-inhibitor Market Outlook Share, 2023 & 2030 (US$M)

China plasma protease c1-inhibitor market size, by drug class, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more